Evidence map›Paper›PMID 31748664›Full record

ArticleScientific reports2019

Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models.

Afshin Beheshti, Kristen Stevenson, Charles Vanderburg, Dashnamoorthy Ravi, J Tyson McDonald, Amanda L Christie, Kay Shigemori, Hallie Jester, David M Weinstock, Andrew M Evens

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Afshin BeheshtiWYLE, NASA Ames Research Center, Moffett Field, CA, USA. afshin.beheshti@nasa.gov.
Kristen StevensonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Charles VanderburgHarvard Medical School, Boston, MA, USA.
Dashnamoorthy RaviDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
J Tyson McDonaldCancer Research Center and Department of Physics, Hampton University, Virginia, USA.
Amanda L ChristieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kay ShigemoriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hallie JesterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David M WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew M EvensDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Funding

MAP Kinase Signaling in Lymphoma: A Novel Therapeutic ParadigmR01CA164311 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI EVENS, ANDREW M, GARTENHAUS, RONALD B · 2012 to 2015
$1.4M
NCI NIH HHS R01 CA164311
6 · The paper itself

Abstract

There remains a need to identify new sensitive diagnostic and predictive blood-based platforms in lymphoma. We previously discovered a novel circulating microRNA (miRNA) signature in a Smurf2-deficient mouse model that spontaneously develops diffuse large B-cell lymphoma (DLBCL). Herein, we investigated this 10-miRNA signature (miR-15a, let-7c, let-7b, miR-27a, miR-10b, miR-18a, miR-497, miR-130a, miR24, and miR-155) in human lymphoma cell lines, mice engrafted with patient-derived xenografts (PDXs), and DLBCL patient serum samples leveraging systems biology analyses and droplet digital PCR (ddPCR) technology. Overall, 90% of the miRNAs were enriched in PDX DLBCL models and human lymphoma cell lines. Circulating miRNAs from the serum of 86 DLBCL patients were significantly increased compared with healthy controls and had similar patterns to the murine models. Strikingly, miRNAs were identified up to 27-fold higher levels in the serum of PDX-bearing mice and human patients compared with lymphoma cell lysates, suggesting a concentration of these factors over time within sera. Using cut-points from recursive partitioning analysis, we derived a 5-miRNA signature (let-7b, let-7c, miR-18a, miR-24, and miR-15a) with a classification rate of 91% for serum from patients with DLBCL versus normal controls. In addition, higher levels of circulating let-7b miRNA were associated with more advanced stage disease (i.e., III-IV vs. I-II) in DLBCL patients and higher levels of miR-27a and miR-24 were associated with MYC rearrangement. Taken together, circulating multi-miRNAs were readily detectable in pre-clinical cell line and human lymphoma models as well as in DLBCL patients where they appeared to distinguish clinico-pathologic subtypes and disease features.

Indexed as

AdolescentAnimalsBiomarkers, TumorCell Line, TumorCirculating MicroRNAFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseMaleMiceBiomarkers, TumorCirculating MicroRNA

Identifiers

PMID31748664
PMCPMC6868195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.